Scarica l'app Stockscreener
0.80
0.00%
0.00
Dopo l'orario di chiusura:
.80
Precedente Chiudi:
$0.80
Aprire:
$0.8
Volume 24 ore:
60,442
Relative Volume:
0.35
Capitalizzazione di mercato:
$61.82M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.4494
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
-6.41%
1M Prestazione:
-11.81%
6M Prestazione:
-36.00%
1 anno Prestazione:
-78.55%
Intervallo 1D:
$0.78
$0.82
Intervallo di 1 settimana:
$0.77
$0.86
Portata 52W:
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.80 | 61.82M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World
20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World
Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo
Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus
Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India
Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com
AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE
Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo
Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
What is HC Wainwright’s Estimate for PRLD Q2 Earnings? - Defense World
SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 - MyChesCo
Q1 Earnings Forecast for PRLD Issued By HC Wainwright - Defense World
Prelude Therapeutics Reports Q1 2025 Financial Results - TipRanks
JPMorgan Chase & Co. Purchases 55,183 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) Given Buy Rating at HC Wainwright - Defense World
Prelude Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics (PRLD) Rating Reiterated with $5 Target by HC Wainwright | PRLD Stock News - GuruFocus
Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 - MyChesCo
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Prelude Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Bluefield Daily Telegraph
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
JMP Securities Reaffirms Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MSN
JMP maintains $4 target on Prelude Therapeutics stock By Investing.com - Investing.com Canada
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MyChesCo
Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus
Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq
Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN
PRLD stock touches 52-week low at $0.61 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):